Windtree Therapeutics, Inc. (WINT)
NASDAQ: WINT · Real-Time Price · USD
0.510
+0.043 (9.13%)
Nov 20, 2024, 4:00 PM EST - Market closed

Company Description

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases.

The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock.

It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure.

In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials.

Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr.

Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee’s Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program.

The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016.

The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.

Windtree Therapeutics, Inc.
Windtree Therapeutics logo
Country United States
Founded 1992
IPO Date Aug 8, 1995
Industry Biotechnology
Sector Healthcare
Employees 20
CEO Craig Fraser

Contact Details

Address:
2600 Kelly Road, Suite 100
Warrington, Pennsylvania 18976-3622
United States
Phone 215 488 9300
Website windtreetx.com

Stock Details

Ticker Symbol WINT
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000946486
CUSIP Number 97382D303
ISIN Number US97382D4025
Employer ID 94-3171943
SIC Code 2836

Key Executives

Name Position
Craig E. Fraser President, Chief Executive Officer and Chairman
Eric L. Curtis M.B.A. Senior Vice President and Chief Operating Officer
Dr. Steven G. Simonson M.D., M.H.S Senior Vice President and Chief Medical Officer
Jamie McAndrew Senior Vice President, Chief Financial Officer, Chief Accounting Officer, Controller and Corporate Secretary
George Cox Vice President of Technical Operations
Dr. Pratap Paruchuru Executive Director of Clinical Development
Tracy Rarick Head of Operations and Program Management

Latest SEC Filings

Date Type Title
Nov 15, 2024 8-K/A [Amend] Current report
Nov 15, 2024 NT 10-Q Notification of inability to timely file Form 10-Q or 10-QSB
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 8-K Current Report
Oct 28, 2024 8-K Current Report
Oct 28, 2024 424B5 Filing
Oct 4, 2024 8-K Current Report
Oct 1, 2024 8-K Current Report